Oral Semaglutide Sustains Kidney Protection After Switching from Injectables

Type 2 diabetes (T2DM) is a prevalent metabolic disorder often leading to severe complications, including diabetic kidney disease (DKD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications well-established for their cardiovascular and renal benefits in T2DM patients. While landmark trials like FLOW have confirmed the renoprotective effects of subcutaneous semaglutide, there remains limited real-world evidence regarding the long-term renal outcomes when patients transition from injectable GLP-1RAs to the oral formulation of semaglutide.

The study observed that patients transitioning to oral semaglutide generally maintained stable renal function over the three-year follow-up. For instance, the mean estimated glomerular filtration rate (eGFR, a key measure of kidney filtering capacity) showed a minimal decline of -0.5 mL/min/1.73m² per year, which was not statistically significant (p=0.32) compared to baseline. The most important finding was a significant reduction in urine albumin-to-creatinine ratio (UACR, an indicator of kidney damage) by 25% (p<0.01) in patients with baseline albuminuria, indicating improved kidney health. This suggests that the renoprotective benefits of GLP-1RAs are sustained even after transitioning to an oral formulation. Furthermore, body weight was reduced by an average of 3.2 kg (p<0.001), and HbA1c (a measure of average blood sugar) decreased by 0.8% (p<0.001), contributing to overall metabolic improvement.